Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with
lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity,
and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease
(ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.